ACROBiosystems, a global biotechnology company, has entered into a strategic Memorandum of Understanding with DAAN Biotherapeutics, a clinical-stage biotech focused on precision immuno-oncology therapeutics. The collaboration, announced in August 2025, establishes a comprehensive framework designed to accelerate the development and commercialization of next-generation immunotherapies targeting drug-resistant cancers.
Multi-Faceted Partnership Framework
The strategic alliance encompasses three key components: stable supply of high-performance bioreagents, technical cooperation for immuno-oncology drug development, and joint research and data sharing. This partnership aims to break current barriers in immunotherapy by integrating ACROBiosystems' high-performance bioreagent and GMP-grade raw material expertise with DAAN's proprietary immune-modulation platform.
ACROBiosystems brings to the collaboration its Resilient Supply™ model, which provides high-quality GMP-grade raw materials and quality control testing solutions with enhanced flexibility and regulatory compliance. The company's GMP Manufacturing Base features smart modular design and dual ISO 9001/GMP certification, ensuring agile production of cytokines, activation antibodies, nucleases, and matrix proteins for large-scale biopharmaceutical manufacturing.
Precision Immune-Modulation Technology
DAAN Biotherapeutics has developed a proprietary precision immune-modulation platform that selectively activates T cells within the tumor microenvironment. By finely tuning the activation threshold of T cells, this next-generation technology is designed to overcome the toxicity and therapeutic resistance issues of conventional immunotherapies caused by non-specific stimulation, thereby enhancing efficacy while minimizing adverse effects.
The company is developing precision TCR-T cell therapies specifically targeting drug-resistant EGFR-mutant cancers. Its lead pipeline has completed preclinical development and is preparing for entry into global clinical trials. Beyond oncology, DAAN is expanding the applications of its platform to autoimmune and rare diseases.
Industry Impact and Leadership Perspectives
"ACROBiosystems is a trusted partner with a quality-focused philosophy and technological innovation capabilities," stated Byoung Chul Cho, CEO of DAAN Biotherapeutics. "This collaboration will not only enhance our efficiency in transitioning from preclinical to clinical development but also accelerate our entry into global clinical trials."
Yong Chan Cho, Country Manager of ACROBiosystems Korea, emphasized the strategic significance of the partnership: "This collaboration with DAAN Biotherapeutics, which possesses unparalleled technological expertise in the field of immuno-oncology, marks a highly meaningful strategic milestone. We expect this partnership to generate positive synergies not only in precision therapeutics but also across the broader Korean biotech industry."
Company Backgrounds and Capabilities
Founded in 2010 and publicly listed in 2021, ACROBiosystems Group maintains a global presence with offices, R&D centers, and production bases in over 10 cities across the United States, Switzerland, England, and Germany. The company has established long-term partnerships with leading pharmaceutical enterprises including Pfizer, Novartis, and Johnson & Johnson, along with numerous academic institutes.
DAAN Biotherapeutics, founded in 2021 by Dr. Byoung Chul Cho of Yonsei Cancer Center, has recently raised over KRW 28 billion in cumulative funding through Series A financing. The company is actively participating in Korea's National New Drug Development Program and other government technology commercialization initiatives, positioning itself as a key player in the precision immuno-oncology space.
